Literature DB >> 10723069

Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides.

Q S Chen1, B L Kagan, Y Hirakura, C W Xie.   

Abstract

Although it is generally believed that amyloid beta (Abeta) peptides contribute to the pathogenesis of Alzheimer's disease, the precise role of these peptides in the development of memory loss of Alzheimer's disease, has not been fully understood. The present study examined the effect of several synthetic Abeta peptides on long-term potentiation (LTP), a cellular model of learning and memory, in rat hippocampal slices. Brief perfusion of slices with low concentrations (200 nM or 1 microM) of Abeta(1-42), Abeta(1-40) or their active fragment Abeta(25--35) significantly inhibited LTP induction without affecting the basal synaptic transmission and posttetanic potentiation in the dentate medial perforant path. A similar effect of Abeta(25-35) was also observed in the Schaffer collateral-CA1 pathway. When comparing actions of several Abeta variants derived from Abeta(25-35), the N-terminal sequence of Abeta(25-35) was found necessary for inhibiting LTP. In addition, Abeta variants lacking neurotoxic action and aggregating property were also able to block LTP, suggesting that this effect was neurotoxicity independent. Our findings demonstrated that subneurotoxic concentrations of Abeta peptides could strongly suppress long-term synaptic plasticity in the hippocampus. Such an effect might underlie the memory deficits seen in Alzheimer's disease before neuronal cell loss. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10723069     DOI: 10.1002/(SICI)1097-4547(20000401)60:1<65::AID-JNR7>3.0.CO;2-Q

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  76 in total

1.  Administration of aggregated beta-amyloid peptide (25-35) induces changes in long-term potentiation in the hippocampus in vivo.

Authors:  V V Trubetskaya; M Yu Stepanichev; M V Onufriev; N A Lazareva; V A Markevich; N V Gulyaeva
Journal:  Neurosci Behav Physiol       Date:  2003-02

Review 2.  Synaptic plasticity in animal models of early Alzheimer's disease.

Authors:  Michael J Rowan; Igor Klyubin; William K Cullen; Roger Anwyl
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-04-29       Impact factor: 6.237

Review 3.  Amyloid-β peptide: Dr. Jekyll or Mr. Hyde?

Authors:  Daniela Puzzo; Ottavio Arancio
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 4.  Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

5.  Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats.

Authors:  Yu-Fang Cheng; Chuang Wang; Huan-Bing Lin; Yun-Feng Li; Ying Huang; Jiang-Ping Xu; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2010-07-17       Impact factor: 4.530

6.  Protection against beta-amyloid induced abnormal synaptic function and cell death by Ginkgolide J.

Authors:  Ottavio Vitolo; Bing Gong; Zixuan Cao; Hideki Ishii; Stanislav Jaracz; Koji Nakanishi; Ottavio Arancio; Sergei V Dzyuba; Roger Lefort; Michael Shelanski
Journal:  Neurobiol Aging       Date:  2007-07-20       Impact factor: 4.673

Review 7.  Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity.

Authors:  Roberto Cappai; Kevin J Barnham
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

8.  Early life nutrient restriction impairs blood-brain metabolic profile and neurobehavior predisposing to Alzheimer's disease with aging.

Authors:  Masatoshi Tomi; Yuanzi Zhao; Shanthie Thamotharan; Bo-Chul Shin; Sherin U Devaskar
Journal:  Brain Res       Date:  2012-12-07       Impact factor: 3.252

9.  Inhibition of the Motor Protein Eg5/Kinesin-5 in Amyloid β-Mediated Impairment of Hippocampal Long-Term Potentiation and Dendritic Spine Loss.

Authors:  Ronald K Freund; Emily S Gibson; Huntington Potter; Mark L Dell'Acqua
Journal:  Mol Pharmacol       Date:  2016-03-08       Impact factor: 4.436

10.  Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide.

Authors:  Qinwen Wang; Michael J Rowan; Roger Anwyl
Journal:  J Neurosci       Date:  2004-07-07       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.